;PMID: 9018769
;source_file_771.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:47..103] = [t:47..103]
;2)section:[e:107..183] = [t:107..183]
;3)section:[e:187..265] = [t:187..265]
;4)sentence:[e:269..280] = [t:269..280]
;5)sentence:[e:281..444] = [t:281..444]
;6)sentence:[e:445..557] = [t:445..557]
;7)sentence:[e:558..566] = [t:558..566]
;8)sentence:[e:567..857] = [t:567..857]
;9)sentence:[e:858..866] = [t:858..866]
;10)sentence:[e:867..954] = [t:867..954]
;11)sentence:[e:955..1186] = [t:955..1186]
;12)sentence:[e:1187..1350] = [t:1187..1350]
;13)sentence:[e:1351..1363] = [t:1351..1363]
;14)sentence:[e:1365..1565] = [t:1365..1565]
;15)sentence:[e:1566..1746] = [t:1566..1746]
;16)section:[e:1750..1794] = [t:1750..1794]

;section 0 Span:0..42
;Scand J Gastroenterol  1997 Jan;32(1):62-9
(SEC
  (FRAG (NNP:[0..5] Scand) (NNP:[6..7] J) (NNP:[8..21] Gastroenterol)
        (CD:[23..27] 1997) (CC:[28..35] Jan;32-LRB-) (CD:[35..36] 1)
        (-RRB-:[36..37] -RRB-) (CD:[37..40] :62) (::[40..41] -) (CD:[41..42] 9)))

;sentence 1 Span:47..103
;K-ras mutations and prognosis in large-bowel carcinomas.
;[47..52]:gene-rna:"K-ras"
;[80..102]:malignancy:"large-bowel carcinomas"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[47..52] K-ras) (NNS:[53..62] mutations))
      (CC:[63..66] and)
      (NP (NN:[67..76] prognosis)))
    (PP-LOC (IN:[77..79] in)
      (NP
        (NML (JJ:[80..85] large) (HYPH:[85..86] -) (NN:[86..91] bowel))
        (NNS:[92..102] carcinomas)))
    (.:[102..103] .)))

;section 2 Span:107..183
;Andersen SN, Lovig T, Breivik J, Lund E, Gaudernack G, Meling GI, Rognum TO.
(SEC
  (FRAG (NNP:[107..115] Andersen) (NNP:[116..118] SN) (,:[118..119] ,)
        (NNP:[120..125] Lovig) (NNP:[126..127] T) (,:[127..128] ,)
        (NNP:[129..136] Breivik) (NNP:[137..139] J,) (NNP:[140..144] Lund)
        (NNP:[145..146] E) (,:[146..147] ,) (NNP:[148..158] Gaudernack)
        (NNP:[159..160] G) (,:[160..161] ,) (NNP:[162..168] Meling)
        (NNP:[169..171] GI) (,:[171..172] ,) (NNP:[173..179] Rognum)
        (NNP:[180..182] TO) (.:[182..183] .)))

;section 3 Span:187..265
;Institute of Forensic Medicine, National Hospital, University of Oslo,
;Norway.
(SEC
  (FRAG (NNP:[187..196] Institute) (IN:[197..199] of) (NNP:[200..208] Forensic)
        (NNP:[209..217] Medicine) (,:[217..218] ,) (NNP:[219..227] National)
        (NNP:[228..236] Hospital) (,:[236..237] ,) (NNP:[238..248] University)
        (IN:[249..251] of) (NNP:[252..256] Oslo) (,:[256..257] ,)
        (NNP:[258..264] Norway) (.:[264..265] .)))

;sentence 4 Span:269..280
;BACKGROUND:
(SENT
  (NP (NN:[269..279] BACKGROUND) (::[279..280] :)))

;sentence 5 Span:281..444
;Colorectal carcinogenesis is regarded as a multistep process  involving
;several genetic alterations, with mutation in the K-ras gene in about  half
;of the tumours.
;[403..408]:gene-rna:"K-ras"
;[436..443]:malignancy:"tumours"
(SENT
  (S
    (NP-SBJ-1 (JJ:[281..291] Colorectal) (NN:[292..306] carcinogenesis))
    (VP (VBZ:[307..309] is)
      (VP (VBN:[310..318] regarded)
        (NP-1 (-NONE-:[318..318] *))
        (PP-CLR (IN:[319..321] as)
          (NP
            (NP (DT:[322..323] a) (JJ:[324..333] multistep)
                (NN:[334..341] process))
            (VP (VBG:[343..352] involving)
              (NP (JJ:[353..360] several) (JJ:[361..368] genetic)
                  (NNS:[369..380] alterations)))
            (,:[380..381] ,)
            (PP (IN:[382..386] with)
              (NP
                (NP (NN:[387..395] mutation))
                (PP-LOC (IN:[396..398] in)
                  (NP (DT:[399..402] the) (NN:[403..408] K-ras)
                      (NN:[409..413] gene)))
                (PP-LOC (IN:[414..416] in)
                  (NP
                    (NP
                      (QP (RB:[417..422] about) (NN:[424..428] half)))
                    (PP (IN:[429..431] of)
                      (NP (DT:[432..435] the) (NNS:[436..443] tumours)))))))))))
    (.:[443..444] .)))

;sentence 6 Span:445..557
;We aimed at clarifying the role of this genetic alteration  related to
;survival and clinicopathologic variables.
(SENT
  (S
    (NP-SBJ (PRP:[445..447] We))
    (VP (VBD:[448..453] aimed)
      (PP-CLR (IN:[454..456] at)
        (S-NOM
          (NP-SBJ (-NONE-:[456..456] *))
          (VP (VBG:[457..467] clarifying)
            (NP
              (NP (DT:[468..471] the) (NN:[472..476] role))
              (PP (IN:[477..479] of)
                (NP
                  (NP
                    (NP (DT:[480..484] this) (JJ:[485..492] genetic)
                        (NN:[493..503] alteration))
                    (ADJP (JJ:[505..512] related)
                      (PP (TO:[513..515] to)
                        (NP (NN:[516..524] survival)))))
                  (CC:[525..528] and)
                  (NP (JJ:[529..546] clinicopathologic)
                      (NNS:[547..556] variables)))))))))
    (.:[556..557] .)))

;sentence 7 Span:558..566
;METHODS:
(SENT
  (NP (NNS:[558..565] METHODS) (::[565..566] :)))

;sentence 8 Span:567..857
;One hundred  large-bowel carcinomas operated on between 1978 and 1982 were
;studied for the  presence of point mutations in codons 12 and 13 of the K-ras
;gene, using  enriched polymerase chain reaction amplification, restriction
;fragment length  polymorphism analysis, and direct sequencing.
;[580..602]:malignancy:"large-bowel carcinomas"
;[671..686]:variation-type:"point mutations"
;[690..699]:variation-location:"codons 12"
;[690..696]...[704..706]:variation-location:"codons"..."13"
;[714..719]:gene-rna:"K-ras"
;[742..752]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (QP (CD:[567..570] One) (CD:[571..578] hundred))
        
        (NML (JJ:[580..585] large) (HYPH:[585..586] -) (NN:[586..591] bowel))
        (NNS:[592..602] carcinomas))
      (VP (VBN:[603..611] operated)
        (PP (IN:[612..614] on)
          (NP (-NONE-:[614..614] *)))
        (PP-TMP (IN:[615..622] between)
          (NP (CD:[623..627] 1978) (CC:[628..631] and) (CD:[632..636] 1982)))))
    (VP (VBD:[637..641] were)
      (VP (VBN:[642..649] studied)
        (NP-2 (-NONE-:[649..649] *))
        (PP-PRP (IN:[650..653] for)
          (NP
            (NP (DT:[654..657] the) (NN:[659..667] presence))
            (PP (IN:[668..670] of)
              (NP (NN:[671..676] point) (NNS:[677..686] mutations)))
            (PP-LOC (IN:[687..689] in)
              (NP
                (NP
                  (NP
                    (NML-1 (NNS:[690..696] codons))
                    (CD:[697..699] 12))
                  (CC:[700..703] and)
                  (NP
                    (NML-1 (-NONE-:[703..703] *P*))
                    (CD:[704..706] 13)))
                (PP (IN:[707..709] of)
                  (NP (DT:[710..713] the) (NN:[714..719] K-ras)
                      (NN:[720..724] gene)))))))
        (,:[724..725] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[725..725] *))
          (VP (VBG:[726..731] using)
            (NP
              (NP (JJ:[733..741] enriched)
                (NML (NN:[742..752] polymerase) (NN:[753..758] chain)
                     (NN:[759..767] reaction))
                (NN:[768..781] amplification))
              (,:[781..782] ,)
              (NP
                (NML
                  (NML
                    (NML (NN:[783..794] restriction) (NN:[795..803] fragment))
                    (NN:[804..810] length))
                  (NN:[812..824] polymorphism))
                (NN:[825..833] analysis))
              (,:[833..834] ,) (CC:[835..838] and)
              (NP (JJ:[839..845] direct) (NN:[846..856] sequencing)))))))
    (.:[856..857] .)))

;sentence 9 Span:858..866
;RESULTS:
(SENT
  (NP (NNS:[858..865] RESULTS) (::[865..866] :)))

;sentence 10 Span:867..954
;Forty mutations were  found (40%): 31 in codon 12 and 9 in codon 13, 7
;different types.
;[873..882]:variation-event:"mutations"
;[908..916]:variation-location:"codon 12"
;[926..934]:variation-location:"codon 13"
(SENT
  (S
    (NP-SBJ-1 (CD:[867..872] Forty) (NNS:[873..882] mutations))
    (VP (VBD:[883..887] were)
      (VP (VBN:[889..894] found)
        (NP-1 (-NONE-:[894..894] *))
        (PRN (-LRB-:[895..896] -LRB-)
          (NP (CD:[896..898] 40) (NN:[898..899] %))
          (-RRB-:[899..900] -RRB-))
        (::[900..901] :)
        (FRAG
          (S
            (S
              (NP-SBJ (CD:[902..904] 31))
              (PP-PRD (IN:[905..907] in)
                (NP (NN:[908..913] codon) (CD:[914..916] 12))))
            (CC:[917..920] and)
            (S
              (NP-SBJ (CD:[921..922] 9))
              (PP-PRD (IN:[923..925] in)
                (NP
                  (NML (NN:[926..931] codon) (CD:[932..934] 13))))))
          (,:[934..935] ,)
          (NP (CD:[936..937] 7) (JJ:[938..947] different) (NNS:[948..953] types)))))
    (.:[953..954] .)))

;sentence 11 Span:955..1186
;There was no  relationship between tumours with and without K-ras mutations
;with regard to  Dukes' stages, age or sex of the patient, tumour
;localization, histologic grade,  DNA ploidy pattern, HLA-DR staining pattern,
;or survival.
;[990..997]:malignancy:"tumours"
;[1015..1020]:gene-rna:"K-ras"
;[1021..1030]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ (EX:[955..960] There))
    (VP (VBD:[961..964] was)
      (NP-PRD
        (NP (DT:[965..967] no) (NN:[969..981] relationship))
        (PP (IN:[982..989] between)
          (NP
            (NP (NNS:[990..997] tumours))
            (PP (IN:[998..1002] with) (CC:[1003..1006] and)
                (IN:[1007..1014] without)
              (NP (NN:[1015..1020] K-ras) (NNS:[1021..1030] mutations))))))
      (PP (IN:[1031..1035] with)
        (NP
          (NP (NN:[1036..1042] regard))
          (PP (TO:[1043..1045] to)
            (NP
              (NP
                (NML (NNP:[1047..1052] Dukes) (POS:[1052..1053] '))
                (NNS:[1054..1060] stages))
              (,:[1060..1061] ,)
              (NP (NN:[1062..1065] age))
              (CC:[1066..1068] or)
              (NP
                (NP (NN:[1069..1072] sex))
                (PP (IN:[1073..1075] of)
                  (NP (DT:[1076..1079] the) (NN:[1080..1087] patient))))
              (,:[1087..1088] ,)
              (NP (NN:[1089..1095] tumour) (NN:[1096..1108] localization))
              (,:[1108..1109] ,)
              (NP (JJ:[1110..1120] histologic) (NN:[1121..1126] grade))
              (,:[1126..1127] ,)
              (NP
                (NML (NN:[1129..1132] DNA) (NN:[1133..1139] ploidy))
                (NN:[1140..1147] pattern))
              (,:[1147..1148] ,)
              (NP
                (NML (NN:[1149..1155] HLA-DR) (NN:[1156..1164] staining))
                (NN:[1165..1172] pattern))
              (,:[1172..1173] ,) (CC:[1174..1176] or)
              (NP (NN:[1177..1185] survival)))))))
    (.:[1185..1186] .)))

;sentence 12 Span:1187..1350
;Samples from 5  different localizations in 7 carcinomas showed identical
;K-ras mutation pattern,  as did 19 recurrences/ metastases originating from
;11 carcinomas.
;[1232..1242]:malignancy:"carcinomas"
;[1260..1265]:gene-rna:"K-ras"
;[1339..1349]:malignancy:"carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1187..1194] Samples))
      (PP (IN:[1195..1199] from)
        (NP
          (NP (CD:[1200..1201] 5) (JJ:[1203..1212] different)
              (NNS:[1213..1226] localizations))
          (PP-LOC (IN:[1227..1229] in)
            (NP (CD:[1230..1231] 7) (NNS:[1232..1242] carcinomas))))))
    (VP (VBD:[1243..1249] showed)
      (NP (JJ:[1250..1259] identical)
        (NML (NN:[1260..1265] K-ras) (NN:[1266..1274] mutation))
        (NN:[1275..1282] pattern))
      (,:[1282..1283] ,)
      (SBAR-ADV (IN:[1285..1287] as)
        (SINV (VBD:[1288..1291] did)
          (NP-SBJ
            (NP (CD:[1292..1294] 19) (NNS:[1295..1306] recurrences)
                (SYM:[1306..1307] /) (NNS:[1308..1318] metastases))
            (VP (VBG:[1319..1330] originating)
              (PP (IN:[1331..1335] from)
                (NP (CD:[1336..1338] 11) (NNS:[1339..1349] carcinomas)))))
          (VP (-NONE-:[1349..1349] *?*)))))
    (.:[1349..1350] .)))

;sentence 13 Span:1351..1363
;CONCLUSIONS:
(SENT
  (NP (NNS:[1351..1362] CONCLUSIONS) (::[1362..1363] :)))

;sentence 14 Span:1365..1565
;When present, the primary tumour shows homogeneous distribution of K-ras 
;mutation, and the mutation follows the carcinoma in the secondary deposit, 
;regardless of lymphogenous or hematogenous spread.
;[1383..1397]:malignancy:"primary tumour"
;[1432..1437]:gene-rna:"K-ras"
;[1439..1447]:variation-event:"mutation"
;[1453..1465]:variation-event:"the mutation"
;[1478..1487]:malignancy:"carcinoma"
(SENT
  (S
    (S
      (SBAR (WRB:[1365..1369] When)
        (S
          (NP-SBJ (-NONE-:[1369..1369] *))
          (ADJP-PRD (NN:[1370..1377] present))))
      (,:[1377..1378] ,)
      (NP-SBJ (DT:[1379..1382] the)
         (JJ:[1383..1390] primary) (NN:[1391..1397] tumour))
      (VP (VBZ:[1398..1403] shows)
        (NP
          (NP (JJ:[1404..1415] homogeneous) (NN:[1416..1428] distribution))
          (PP (IN:[1429..1431] of)
            (NP (NN:[1432..1437] K-ras) (NN:[1439..1447] mutation))))))
    (,:[1447..1448] ,) (CC:[1449..1452] and)
    (S
      (NP-SBJ (DT:[1453..1456] the) (NN:[1457..1465] mutation))
      (VP (VBZ:[1466..1473] follows)
        (NP (DT:[1474..1477] the) (NN:[1478..1487] carcinoma))
        (PP-LOC (IN:[1488..1490] in)
          (NP (DT:[1491..1494] the) (JJ:[1495..1504] secondary)
              (NN:[1505..1512] deposit)))
        (,:[1512..1513] ,)
        (ADVP (RB:[1515..1525] regardless)
          (PP (IN:[1526..1528] of)
            (NP
              (NP (JJ:[1529..1541] lymphogenous)
                (NML-1 (-NONE-:[1541..1541] *P*)))
              (CC:[1542..1544] or)
              (NP (JJ:[1545..1557] hematogenous)
                (NML-1 (NN:[1558..1564] spread))))))))
    (.:[1564..1565] .)))

;sentence 15 Span:1566..1746
;The presence of K-ras  mutation does not seem to have prognostic significance
;for the patient, and the  precise nucleotide change is furthermore not
;predictive of tumour behaviour.
;[1582..1587]:gene-rna:"K-ras"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (DT:[1566..1569] The) (NN:[1570..1578] presence))
        (PP (IN:[1579..1581] of)
          (NP (NN:[1582..1587] K-ras) (NN:[1589..1597] mutation))))
      (VP (VBZ:[1598..1602] does) (RB:[1603..1606] not)
        (VP (VB:[1607..1611] seem)
          (S
            (NP-SBJ-1 (-NONE-:[1611..1611] *))
            (VP (TO:[1612..1614] to)
              (VP (VB:[1615..1619] have)
                (NP
                  (NP (JJ:[1620..1630] prognostic)
                      (NN:[1631..1643] significance))
                  (PP (IN:[1644..1647] for)
                    (NP (DT:[1648..1651] the) (NN:[1652..1659] patient))))))))))
    (,:[1659..1660] ,) (CC:[1661..1664] and)
    (S
      (NP-SBJ (DT:[1665..1668] the) (JJ:[1670..1677] precise)
              (NN:[1678..1688] nucleotide) (NN:[1689..1695] change))
      (VP (VBZ:[1696..1698] is)
        (ADVP (RB:[1699..1710] furthermore))
        (RB:[1711..1714] not)
        (ADJP-PRD (JJ:[1715..1725] predictive)
          (PP (IN:[1726..1728] of)
            (NP (NN:[1729..1735] tumour) (NN:[1736..1745] behaviour))))))
    (.:[1745..1746] .)))

;section 16 Span:1750..1794
;PMID: 9018769 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1750..1754] PMID) (::[1754..1755] :) (CD:[1756..1763] 9018769)
        (NN:[1764..1765] -LSB-) (NNP:[1765..1771] PubMed) (::[1772..1773] -)
        (NN:[1774..1781] indexed) (IN:[1782..1785] for)
        (NNP:[1786..1794] MEDLINE-RSB-)))
